Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised, Double-Blind, Double Dummy, Placebo-Controlled, Parallel-Group Efficacy and Safety Comparison of One-Year Treatment of Two Doses (5mcg (2 Actuations of 2.5 Mcg) and 10mcg (2 Actuations of 5mcg)) of BI 1744 CL Inhalation Solution Delivered by the Respimat Inhaler, and One Dose (12mcg) of Foradil Delivered by the Aerolizer Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Next Previous
Trial Profile

Randomised, Double-Blind, Double Dummy, Placebo-Controlled, Parallel-Group Efficacy and Safety Comparison of One-Year Treatment of Two Doses (5mcg (2 Actuations of 2.5 Mcg) and 10mcg (2 Actuations of 5mcg)) of BI 1744 CL Inhalation Solution Delivered by the Respimat Inhaler, and One Dose (12mcg) of Foradil Delivered by the Aerolizer Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 21 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olodaterol (Primary) ; Formoterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Sponsors Boehringer Ingelheim Pharmaceuticals

Most Recent Events

  • 24 May 2017 Results assessing long-term safety profile of olodaterol from NCT00793624 and NCT00796653 trials presented at the 113th International Conference of the American Thoracic Society
  • 11 Sep 2013 Pooled safety analysis results presented at the 23rd Annual Congress of the European Respiratory Society.
  • 11 Sep 2013 Results reporting lung function presented at the 23rd Annual Congress of the European Respiratory Society.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top